Bliss GVS Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 7:45 am

Competitors of Bliss GVS Pharma Ltd

All Competitor Stocks of Bliss GVS Pharma Ltd

Quarterly Result

Last Updated: August 1, 2025, 11:10 pm

Below is a detailed analysis of the quarterly data for Bliss GVS Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 207.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 207.00 Cr., marking an increase of 9.00 Cr..
• For Expenses, as of Jun 2025, the value is 166.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 177.00 Cr. (Mar 2025) to 166.00 Cr., marking a decrease of 11.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 20.00 Cr..
• For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 11.00% (Mar 2025) to 20.00%, marking an increase of 9.00%.
• For Other Income, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 23.00 Cr..
• For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2025) to 63.00 Cr., marking an increase of 40.00 Cr..
• For Tax %, as of Jun 2025, the value is 30.00%. The value appears to be increasing, which may not be favorable. It has increased from 29.00% (Mar 2025) to 30.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2025) to 44.00 Cr., marking an increase of 27.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 4.08. The value appears strong and on an upward trend. It has increased from 1.47 (Mar 2025) to 4.08, marking an increase of 2.61.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:38 am

Growth

Last Updated: September 5, 2025, 1:05 am

Balance Sheet

Last Updated: July 25, 2025, 3:28 pm

Below is a detailed analysis of the balance sheet data for Bliss GVS Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,040.00 Cr.. The value appears strong and on an upward trend. It has increased from 957.00 Cr. (Mar 2024) to 1,040.00 Cr., marking an increase of 83.00 Cr..
• For Borrowings, as of Mar 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 100.00 Cr. (Mar 2024) to 88.00 Cr., marking a decrease of 12.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 162.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 145.00 Cr. (Mar 2024) to 162.00 Cr., marking an increase of 17.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,301.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 406.00 Cr.. The value appears strong and on an upward trend. It has increased from 370.00 Cr. (Mar 2024) to 406.00 Cr., marking an increase of 36.00 Cr..
• For CWIP, as of Mar 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 21.00 Cr., marking an increase of 13.00 Cr..
• For Investments, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
• For Other Assets, as of Mar 2025, the value is 870.00 Cr.. The value appears strong and on an upward trend. It has increased from 830.00 Cr. (Mar 2024) to 870.00 Cr., marking an increase of 40.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,301.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..

Notably, the Reserves (1,040.00 Cr.) exceed the Borrowings (88.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Bliss GVS Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 8.02. This value is within the healthy range. It has increased from 7.23 (Mar 24) to 8.02, marking an increase of 0.79.
• For Diluted EPS (Rs.), as of Mar 25, the value is 7.95. This value is within the healthy range. It has increased from 7.11 (Mar 24) to 7.95, marking an increase of 0.84.
• For Cash EPS (Rs.), as of Mar 25, the value is 11.36. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 11.36, marking an increase of 1.05.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 76.85. It has increased from 73.57 (Mar 24) to 76.85, marking an increase of 3.28.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 15.49. This value is within the healthy range. It has decreased from 17.13 (Mar 24) to 15.49, marking a decrease of 1.64.
• For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 12.69, marking a decrease of 1.92.
• For PBT / Share (Rs.), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 11.16 (Mar 24) to 11.92, marking an increase of 0.76.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 7.79 (Mar 24) to 8.57, marking an increase of 0.78.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.00. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 8.00, marking an increase of 0.79.
• For PBDIT Margin (%), as of Mar 25, the value is 20.15. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 20.15, marking a decrease of 3.13.
• For PBIT Margin (%), as of Mar 25, the value is 16.51. This value is within the healthy range. It has decreased from 19.86 (Mar 24) to 16.51, marking a decrease of 3.35.
• For PBT Margin (%), as of Mar 25, the value is 15.51. This value is within the healthy range. It has increased from 15.17 (Mar 24) to 15.51, marking an increase of 0.34.
• For Net Profit Margin (%), as of Mar 25, the value is 11.14. This value exceeds the healthy maximum of 10. It has increased from 10.59 (Mar 24) to 11.14, marking an increase of 0.55.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.41. This value is within the healthy range. It has increased from 9.79 (Mar 24) to 10.41, marking an increase of 0.62.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.02. This value is below the healthy minimum of 15. It has increased from 7.80 (Mar 24) to 8.02, marking an increase of 0.22.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.84. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.84, marking a decrease of 2.67.
• For Return On Assets (%), as of Mar 25, the value is 6.48. This value is within the healthy range. It has increased from 6.21 (Mar 24) to 6.48, marking an increase of 0.27.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. There is no change compared to the previous period (Mar 24) which recorded 0.64.
• For Current Ratio (X), as of Mar 25, the value is 4.81. This value exceeds the healthy maximum of 3. It has decreased from 5.08 (Mar 24) to 4.81, marking a decrease of 0.27.
• For Quick Ratio (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 2. It has decreased from 4.34 (Mar 24) to 4.08, marking a decrease of 0.26.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.57. This value is within the healthy range. It has increased from 3.06 (Mar 24) to 6.57, marking an increase of 3.51.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.22. This value is below the healthy minimum of 20. It has decreased from 6.90 (Mar 24) to 6.22, marking a decrease of 0.68.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.61. This value is below the healthy minimum of 20. It has decreased from 5.11 (Mar 24) to 4.61, marking a decrease of 0.50.
• For Earning Retention Ratio (%), as of Mar 25, the value is 93.78. This value exceeds the healthy maximum of 70. It has increased from 93.10 (Mar 24) to 93.78, marking an increase of 0.68.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.39. This value exceeds the healthy maximum of 70. It has increased from 94.89 (Mar 24) to 95.39, marking an increase of 0.50.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 20.10. This value is within the healthy range. It has decreased from 25.95 (Mar 24) to 20.10, marking a decrease of 5.85.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.12. This value is within the healthy range. It has decreased from 17.03 (Mar 24) to 12.12, marking a decrease of 4.91.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,137.76. It has increased from 1,087.33 (Mar 24) to 1,137.76, marking an increase of 50.43.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.41.
• For EV / EBITDA (X), as of Mar 25, the value is 6.97. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 6.97, marking an increase of 0.91.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
• For Retention Ratios (%), as of Mar 25, the value is 93.77. This value exceeds the healthy maximum of 70. It has increased from 93.09 (Mar 24) to 93.77, marking an increase of 0.68.
• For Price / BV (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.22 (Mar 24) to 1.18, marking a decrease of 0.04.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness